CTOs on the Move

Newport Healthcare

www.newporthealthcare.com

 
Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

egb Advisors

egb Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardiology Consultants of Philadelphia

As America’s largest independent cardiac care practice, CCP is home to the most experienced cardiologists in the Philadelphia region.

Formulated Solutions

Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.

The Pharmacy Examination Board of Canada

The Pharmacy Examination Board of Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.